Key result
Empagliflozin preserves LVEF by ~15 points over control diet in dystrophic mice.
Why the study?
Effective cardiac therapies for cardiomyopathy in Duchenne muscular dystrophy remain limited, and the therapeutic potential of the SGLT2 inhibitor empagliflozin in a DMD mouse model required investigation.
Does empagliflozin (~25 mg/kg/day) preserve left ventricular ejection fraction and myocardial deformation in the DBA2/J-mdx mouse model of Duchenne muscular dystrophy?
Does empagliflozin (~25 mg/kg/day) preserve left ventricular ejection fraction and myocardial deformation in the DBA2/J-mdx mouse model of Duchenne muscular dystrophy?
In a Duchenne muscular dystrophy mouse model, empagliflozin delayed the onset of systolic dysfunction, preserved myocardial deformation and mitochondrial energetics, and improved skeletal muscle torque without renal toxicity.
Answers are grounded in this paper and cite their sources.
Empagliflozin may preserve LVEF in DMD cardiomyopathy models; leaves open translation to patients pending human trials.
Duchenne muscular dystrophy (DMD) is a fatal genetic disorder characterized by skeletal muscle degeneration and cardiomyopathy. Effective cardiac therapies remain limited. This study investigated the therapeutic potential of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMPA) in the dystrophin-deficient DBA2/J- mdx mouse model of DMD. Male mice received control chow or EMPA-containing chow (~25mg/kg/day), and cardiac function was evaluated longitudinally using four-dimensional ultrasound imaging. EMPA did not alter left ventricular mass or volume but delayed the onset of systolic dysfunction, preserving ejection fraction (EF) for 12 weeks and maintaining significantly higher EF through 24 weeks. EMPA also attenuated progressive impairments in systolic and diastolic myocardial deformation. Functional preservation was accompanied by reduced cardiomyocyte hypertrophy and reduced expression of cardiac stress genes. EMPA increased mtDNA copy number, reduced mtDNA damage, preserved the mtDNA-encoded respiratory chain protein MT-CO1, and increased myocardial ATP content, supporting improved mitochondrial integrity and myocardial energetic capacity. In addition, EMPA induced transcriptional changes consistent with enhanced fatty acid and ketone metabolism. Systemically, EMPA improved growth trajectory, preserved relative lean mass, increased skeletal muscle torque, attenuated fiber-type remodeling, and did not adversely affect renal function. Together, these findings support SGLT2 inhibitors as a promising therapeutic strategy for DMD-associated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Zeidler et al. (2026) studied Duchenne muscular dystrophy-associated cardiomyopathy (dystrophin-deficient mdx mouse model) (n=59). Empagliflozin vs. Control chow was evaluated on Left ventricular ejection fraction (LVEF) at 24 weeks assessed by four-dimensional ultrasound (p=<0.0001). Empagliflozin delayed systolic dysfunction and maintained a higher LVEF at 24 weeks compared to control diet in dystrophin-deficient mdx mice.
Synapse has enriched 10 related papers. Consider them for comparative context: